IL17A and chronic obstructive pulmonary disease: IFN-γ, immune receptors, and signaling molecules were highlighted in Tier 3 because IL-6, IL-8, IL-1β, and IL-17 already have clinical or preclinical support in COPD–PA, whereas these Tier-3 targets currently lack comparably robust evidence and remain exploratory.